Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 13, 2004 - Issue 4
Submit an article Journal homepage
199
Views
42
CrossRef citations to date
0
Altmetric
Drug Evaluation

Dronedarone: an amiodarone analogue

Sheila A Doggrell Doggrell Biomedical Communications, 47 Caronia Cresent, Lynfield, Auckland, New Zealand. [email protected]
&
Jules C Hancox Doggrell Biomedical Communications, 47 Caronia Cresent, Lynfield, Auckland, New Zealand. [email protected]
Pages 415-426 | Published online: 02 Mar 2005

Bibliography

  • CARDIAC ARRHYTHMIA SUPPRESSION TRIAL (CAST) INVESTIGATORS: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. iN Eng]. I Med. (1989) 321:406–412.
  • ECHT DS, LIEBSON PR, MITCHELL LB, CAST INVESTIGATORS: Mortality and morbidity in patients receiving encainide, flecainide or placebo: The Cardiac Arrhythmia Suppression Trial. iN Eng]. Med. (1991) 324:781–788.
  • THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL II INVESTIGATORS: Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. iN Eng]. I Med. (1992) 327:227–233.
  • NACCARELLI GV, WOLBRETTE DL, LUCK JC: Results of clinical trials. In: Cardiac electrophysiology from cell to bedside iOld edition) Zipes EP, Jalife J (Eds) (1999):791–798.
  • VISKIN S: Long QT syndromes and torsade de pointes. iLancet (1999) 354:1625–1633.
  • WALDO AL, CAMM AJ, DERUYTER H iet al.: Effects of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. (The SWORD investigators). iLancet (1996) 348:7–12.
  • MOUNSEY JP, DIMARCO JP: Cardiovascular drugs. Dofetilide. iCirculation (2000) 102:2665–2670.
  • RODEN DM: Ibutilide and the treatment of atrial arrhythmias. A new drug-almost unheralded-is now available to US physicians. iCirculation (1996) 94:1499–1502.
  • HONDEGHEM LM, SNYDERS DJ: Class III antiarrhythmic agents have a lot of potential but a long way to go. iCirculation (1990) 81:686–690.
  • GRANT AO: Mechanisms of action of antiarrhythmic drugs: from ion channel blockade to arrhythmia termination. iPacing Clin. Electrophysiol. (1997) 20:432–444.
  • CAMM AJ, YAP YG: What should we expect from the next generation of antiarrhythmic drugs? I iCardiovas. Electrophys. (1999) 10:307–317.
  • NATTEL S: The molecular and ionic specificity of antiarrhythmic drug actions. iCardiovas. Electrophys. (1999) 10:272–282.
  • JANUARY CT, RIDDLE JM: Early afterdepolarizations: Mechanism of induction and block. A role for L-type Ca2+ current. iCirc. Res. (1989) 64:977–990.
  • ZHOU Z, STUDENIK C, JANUARY CT: Properties of E-4031-induced early afterdepolarizations in rabbit ventricular myocytes: Studies using a perforated patch method. In: Potassium channels in normal and abnormal conditions. J Vereecke, PP van Bogaert, F Verdonck (Eds), Leuven University Press, Belgium (1995) 375–379.
  • MAKIELSKI JC, JANUARY CT: Proarrhythmia related to prolongation of repolarization: mechanisms, monitoring, prevention and management. iCardiac Electrophysiol. Rev. (1998) 2:132–135.
  • LIU DW, ANTZELEVITCH C: Characteristics of the delayed rectifier current UK, and IK) in canine ventricular epicardial, mid myocardial and endocardial myocytes. A weaker ILK, contributes to the longer action potential of the M cell. iCirc. Res. (1995) 76:351–365.
  • ANTZELEVITCH C, SICOURI S: Clinical relevance of cardiac arrhythmias generated by afterdepolarisations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. I iAm. Coll Cardiol. (1994) 23:259–277.
  • ANTZELEVITCH C: Repolarizing currents in canine ventricular myocardium. Regional differences and similarities. In: Potassium channels M normal and ipathological conditions. J Vereecke, PP van Bogaert, F Verdonck (Eds) Leuven University Press, Belgium (1995) 256–259.
  • GINTANT GA: Regional differences in IKdensity in canine left ventricle: role of I in electrical heterogeneity. iAm.' Physiol. (1995) 268:H604–H613.
  • SANGUINETTI MC, CURRAN ME, SPECTOR PS: Block of delayed rectifier K+ channels as an antiarrhythmic mechanism. In: Potassium channels in normal and pathological conditions. VereeckeJ, van Bogaert PP, Verdonck F (Eds) Leuven University Press, Belgium (1995):151–166.
  • SAGER PT: New advances in class III antiarrhythmic drug therapy. iCarr. Opin. Cardiol. (2000) 15:41–53.
  • BRIL A, FOREST MC, CHEVAL B, FAIVRE JF: Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. iCardiovasc. Res. (1998) 37:130–140
  • BRIL A, GOUT B, BONHOMME M iet al.: Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. I iPharmacol. Exp. Ther. (1996) 276:637–646.
  • KODAMA I, KAMIYA K, TOYAMA J: Cellular electropharmacology of amiodarone. iCardiovasc. Res. (1997) 35:13–29.
  • DOGGRELL SA: Amiodarone - waxed andwaned and waxed again. iExpert Opin. Pharmacother, (2001) 2:1877–1890.
  • •Recent comprehensive review of amiodarone. H.WATANABE Y, KIMURA J: Inhibitory effect of amiodarone on Na+/Ca2+ exchange current in guinea-pig cardiac myocytes. iBr. Pharmacol. (2000) 131:80–84.
  • KADISH AH, CHEN RF, SCHMALTZ S, MORADY F: Magnitude and time course of beta-adrenergic antagonism during oral amiodarone therapy. I iAm. Coll Cardiol. (1990) 16:1240–1245.
  • BJORNERHEIM R, FROYSAKER T, HANSSON V: Effects of chronic amiodarone treatment on human myocardium beta adrenoceptor density and 424 adenylate cyclase response. iCardiovasc. Res. (1991) 25:503–509.
  • BUDU CE, BALAS N, NAWRATH H, WEGENER JW, SHAINBERG A: Increased cardiac alpha-l-adrenoceptor density in rats following treatment with amiodarone. I iBasic Clin. PhysioL Pharmacol (2001) 12:33–47.
  • HOHNSLOSER SH, KLINGENHEBEN T, SINGH BN: Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. iAnn. Intern. Med. (1994) 121:529–535.
  • SUNDERJI R, KANJI Z, GIN K: Pulmonary effects of low dose amiodarone: a review of the risks and recommendations for surveillance. iCan. Cardiol (2000) 16:1435–1440.
  • ERDOGAN MF, GULEC S, TUTAR E, BASKAL N, ERFOGAN G: A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. iThyroid (2003) 13:205–209.
  • DOVAL HC, NUL DR, GRANCELLI HO iet al.: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en Isuficiencia Cardiaca en Argentina (GESICA). iLancet (1994) 344:493–498.
  • GARGUICHEVICH JJ, RAMOS JL, GAMBARTE A iet al.: Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). iAm. Heart (1995) 130:494–500.
  • SINGH SN, FLETCHER RD, FISHER SG iet al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmias. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. iN Engl. I Med. (1995) 333:77–82.
  • SINGH BN, JEWITT DE, DOWNEY JM, KIRK ES, SONNENBLICK EH: Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials. iClin. Exp. Pharmacol PhysioL (1976) 3:427–442.
  • VALENZUELA C, BENNETT PB: Voltage- and use-dependent modulation of calcium channel current in guinea pig ventricular cells by amiodarone and des-oxo-amiodarone. I iCardiovasc. Pharmacol (1991) 17:894–902.
  • RAATIKAINEN MJ, NAP OLITANO CA, DRUZGALA P, DENNIS DM: Electrophysiological effects of a novel, short-acting and potent ester derivative of amiodarone, ATI-2001, in guinea pig isolated heart. J iPharmacolExp Ther. (1996) 277:1454–1463.
  • •First bdescription bof bthe bshort bacting ATI analogues of amiodarone.
  • MOREY TE, SEUBERT CN, RAATIKAINEN MJ iet al.: Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. iJ. Pharmacol Exp. Ther. (2001) 297:260–266.
  • RAATIKAINEN MJ, MOREY TE, DRUZGALA P iet al.: Potent and reversible effects of ATI-2001 on atrial and atrioventricular nodal electrophysiological properties in guinea pig isolated perfused heart. iJ Pharmacol Exp. Ther. (2000) 295:779–785.
  • KULIER AH, NOVALIJA E, HOGAN Q iet al.: The effects of the new antiarrhythmic E 047/1 on postoperative ischemia-induced arrhythmias in dogs. iAnesth. Analg. (1999) 89:1393–1399.
  • DOMANOVITS H, SCHILLINGER M, LERCHER P iet al.: E 047/1: a new class III antiarrhythmic agent. iCardiovasc. Pharmacol (2000) 35:716–722.
  • GOMBOTA H, VICENZI M, MAHLA E, REHAK P, METZLER H: First clinical experience with the rapid, short-acting amiodarone derivative E 047/1 after cardiac surgery. iEui: Anasethesiol (2002) 19:23–31.
  • HA HR, STIEGER B, GRASSI G, ALTORFER HR, FOLLATH F: Structure-effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination. iEur. Clin. Pharmacol (2000) 55:807–814.
  • SPANIOL M, BRACHER R, HA HR, FOLLATH F, KRAHENBUHL S: Toxicity of amiodarone and amiodarone analogues on isolated rat liver mitochondria. iHepatol. (2001) 35:628–636.
  • CARLSSON B, SINGH BN, TEMCIUC M iet al.: Synthesis and preliminary characterization of a novel antiarrhythmic compound (KB130015) with an improved toxicity profile compared with amiodarone. I iMed. Chem. (2002) 45:623–630.
  • •First bdescription bof bthe bthyroid breceptor bantagonist KB-130015.
  • MACIANSKIENE R, VIAPPIANI S, SIPIDO KR, MUBAGWA K: Slowing of the inactivation of cardiac voltage-dependent sodium channels by the amiodarone derivative 2-methy1-3-(3,5-diiodocarboxymethoxybenzyl)benzofuran (KB130015). I iPharmacol Exp. Ther: (2003) 304:130–138.
  • MACIANSKIENE R, BITO V, RAEYMAEKERS L iet al.: Action potential changes associated with a slowed inactivation of cardiac voltage-gated sodium channels by KB130015. iBr: J. PharmacoL (2003) 139:1469–1479.
  • BRANDTS B, ROLF B, MACIANSKIENE R iet al.: Inhibition of G protein coupled and ATP sensitive potassium currents by 2-methy1-3-(3,5-diiodo-4-carboxymethoxybenzyl) benzofuran (KB130015), an amiodarone derivative. I iPharmacoL Exp. Ther. (2004) 308:134–142.
  • AIMOND F, BECK L, GAUTIER P iet al.:Cellular and iin vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. I iPharmacol Exp. Ther (2000) 292:415–424.
  • •Initial description of the electrophysiology of dronedarone in rats.
  • HIMMEL HM, WETTWER E, LI Q, RAVENS U: Four different components contribute to outward current in rat ventricular myocytes. iAm. I PhysioL (1999) 277:H107–H118.
  • WICKENDEN AD, JEGLA TJ, KAPRIELIAN R, BACKX PH: Regional contributions of Kv1.4, Kv4.2, and Kv4.3 to transient outward K+ current in rat ventricle. iAm. I Physiol (1999) 276:H1599–H1607.
  • VARRO A, TAKACS J, NEMETH M iet al.: Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. iBr. Pharmacol (2001) 133:625–634.
  • •Detailed study of electrophysiology of dronedarone at cellular, tissue and intact heart levels in dog.
  • GAUTIER P, GUILLEMARE E, MARION A iet al.: Electrophysiologic characterization of dronedarone in guinea pig ventricular cells." iCardiovasc. Pharmacol (2003) 41:191–202.
  • •Detailed study of cellular electrophysiology of dronedarone in guinea-pig.
  • THOMAS D, KATHOFER S, ZHANG W iet al.: Acute effects of dronedarone on both Expert Op/n. lnvestig. Drugs (2004) 13(4) components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. iBr. J. Phannacol. (2003) 140:996–1002.
  • •Study providing insight into molecular basis of repolarising K+ current pharmacology of dronedarone.
  • WEERAPURA M, NATTEL S, CHARTIER D, CABALLERO R, HEBERT TE: A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link?' iPhysiol (2002) 540:15–27.
  • WITCHEL HJ, MILNES JT, MITCHESON JS, HANCOX JC: Troubleshooting problems with iin vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. iPhannacol Toxicol Methods (2003) 48:65–80.
  • LALEVEE N, NARGEOT J, BARRERE-LEMAIRE S, GAUTIER P, RICHARD S: Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. iCardiovasc. Electrophysiol (2003) 14:885–890.
  • •Study providing direct evidence for action of dronedarone on cardiac Na+ channels.
  • PITT AD, FERNANDES C, BE WICK NL iet al.: Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone. iCardiovasc. Res. (2003) 57:101–108.
  • SUN W, SARMA JS, SINGH BN: Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. iCardiovasc. Phannacol (2002) 39:677–684.
  • GUILLEMARE E, MARION A, NISATO D, GAUTIER P: Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells." iCardiovasc. Phannacol (2000) 36:802–805.
  • •Study providing evidence for potent action of dronedarone on atrial muscarinic K+ current.
  • ALTOMARE C, BARBUTI A, VISCOMI C, BARUSCOTTI M, DIFRANCESCO D: Effects of dronedarone on acetylcholine-activated current in rabbit SAN cells. iBr. J. Phannacol (2000) 130:1315–1320.
  • CHATELAIN P, MEYSMANS L, MATEAZZI JR, BEAUFORT P, CLINIET M: Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the 13-adrenoceptor and adenylate cyclase in rat heart. iBr. J. Phannacol (1995) 116:1949–1956.
  • HODEIGE D, HEYNDRICKZ JP, CHATELAIN P, MANNING A: SR 33589, a new amiodarone-like antiarrhythmic agent: anti-adrenoceptor activity in anaesthetized and conscious dogs. iEur. Phannacol (1995) 279:25–32.
  • PANTOS C, MOUROUZIS I, DELBRUYERE M iet al: Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. iEur. Phannacol (2002) 444:191–196.
  • VAN BEEREN HC, JONG WM, KAPTEIN E iet al.: Dronedarone acts as a selective inhibitor of 3,5, 3'-tritodothyronine binding to thyroid hormone receptor-alphal : iin vitro and iin vivo evidence. iEndocrinology (2003) 144:552–558.
  • MANNING A, THISSE V, HODEIGE D iet al: SR 33589, a new amiodarone-like antiarrhythmic agent: electrophysiological effects in anesthetized dogs. iCardiovasc. Phannacol (2000) 25:252–261.
  • MANNING AS, BRUYNINCKX C, RAMBOUXJ, CHATELAIN P: SR 33589, a new amiodarone-like agent:: effect on ischemic- and reperfusion-induced arrhythmias in anaesthetized rats. iCardiovasc. Phannacol (1995) 26:453–461.
  • •First description of the effects of dronedarone in an animal model of ischaemic- and reperfusion-induced arrhythmias.
  • ROCHETAING A, BARBE C, KREHER P: Beneficial effects of amiodarone and dronedarone (SR 33589) when applied during low-flow ischemia, on arrhythmia and functional parameters assessed during reperfusion in isolated rat hearts. iJ. Cardiovasc. Phannacol (2001) 38:500–511.
  • FINANCE 0, MANNING A, CHATELAIN P: Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. iCardiovasc. Phannacol (1995) 26:570–576.
  • VERDUN SC, VOS MA, LEUNISSEN HD, VAN OPSTAL JM, WELLENS HJ: Evaluation of the acute electrophysiological effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias. I iCardiovasc. Phannacol (1995) 33:212–222.
  • VAN OPSTAL JM, SCHOENMAKERS M, VERDUYN SC iet al.: Chronic amiodarone evokes no torsade de pointes arrhythmia despite QT lengthening in an animal model of acquired long-QT syndrome. iCirculation (2001) 104:2722–2727.
  • DJANDJIGHIAN L, PLANCHENAULT J, FINANCE 0 iet al.: Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animal with a healed myocardial infarction. iCardiovasc. Phannacol (2000) 36:376–383.
  • TOUBOUL P, BRUGADA J, CAPUCCI A iet al.: Dronedarone for prevention of atrial fibrillation: a dose-ranging study. iEur: Heart J. (2003) 24:1481–1487.
  • •Clinical trial showing dronedarone prevents atrial fibrillation relapses after cardioversion. Websites

Websites

  • http://www.sanofi-synthelabous.com/news/ 192003/20030117.html Sanofi-sythelabous press release (2003).
  • http://es.sanofi-synthelabo.com/Images/ 143_22613.pdf Sanofi-sythelabous research and development presentation for the Merrill Lynch Global Pharmaceutical Conference (2003).
  • http://www.arrhythmia.org/newsite/ clinical_trials.html St Luke's-Roosavelt Hospital Centre clinical trials.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.